Voloridge Investment Management LLC Has $2.19 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Voloridge Investment Management LLC boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 129.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 116,149 shares of the company's stock after purchasing an additional 65,467 shares during the period. Voloridge Investment Management LLC owned 0.25% of Pacira BioSciences worth $2,188,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming grew its position in Pacira BioSciences by 8.0% during the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock worth $124,000 after purchasing an additional 487 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after purchasing an additional 794 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares in the last quarter. Finally, Sterling Capital Management LLC grew its holdings in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after acquiring an additional 1,208 shares in the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Barclays boosted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, Needham & Company LLC lowered their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Stock Down 0.5%

NASDAQ:PCRX traded down $0.14 during trading hours on Friday, reaching $25.79. The company's stock had a trading volume of 595,420 shares, compared to its average volume of 975,524. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -12.70 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.64. The business's 50-day moving average is $25.35 and its 200-day moving average is $23.07.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.